Program Type: New England CEPAC

Interventions of Interest For questions please contact [email protected].

Interventions of Interest For questions please contact [email protected]. Final Documents ICER’s President and CEO Sarah K. Emond, MPP: “The current confusion in the US around vaccine policy is challenging for both health care professionals and the American public. Policymakers, especially public health leaders, need reliable and unbiased assessments of how well therapies work for patients. […]

Intervention of Interest For questions please contact [email protected]. View the Key Stakeholder List. Final Documents

Interventions of Interest ICER assessed the comparative clinical effectiveness and value of sonpiretigene isteparvovec (Nanoscope Therapeautics) for the treatment of advanced retinitis pigmentosa. An independent appraisal committee voted that the current evidence is adequate to demonstrate a net health benefit of sonpiretigene isteparvovec compared to usual care. Final Documents For questions please contact [email protected]. View […]

Interventions of Interest The independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for tabelecleucel when compared to usual care; tabelecleucel would achieve common thresholds for cost-effectiveness if priced between $143,900 to $273,700 per treatment cycle. Final Documents For questions or to request a Spanish translated Report-at-a-Glance or ICER […]